Table 1.
Major Wingspan stent trials with mean time to treatment and complication rates
| Publication | Patients stented (n) | Percentage stented on label for stroke | Periprocedural complications %) | Time to stent from stroke or TIA (days) | |
| HDE trial | Stroke, 200724 | 44 | 93 | 4.5 | 22 |
| US registry |
Stroke, 200727
Stroke, 201128 |
158 | 57 | 6.9 | Not reported |
| NIH registry | Neurology, 200825 | 160 | 61 | 6.2 | 10 |
| SAMMPRIS | New England Journal of Medicine, 20118 | 208 | 8.2 | 14.7 | 7 |
| Jiang | Stroke, 201130 | 100 | 71 | 5.0 | 34 |
| Miao | Stroke, 201529 | 141 | 56 | 4.3 | 19 for TIA/32 for stroke |
| Zhao | Journal of Stroke and Cerebrovascular Diseases, 201633 | 278 | Not reported | 4.3 | 21 |
| Gao | American Journal of Neuroradiology, 201635 | 100 | 50 | 2.0 | 21 |
| Ma | Stroke and Vascular Neurology, 201834 | 141 | 56 | 4.0 | 22 |
| WEAVE | Stroke, 201937 | 152 | 100 | 2.6 | 22 |
HDE, Humanitarian Device Exemption; NIH, National Institutes of Health; SAMMPRIS, Stenting vs Aggressive Medical Therapy for Intracranial Artery Stenosis; TIA, transient ischaemic attack; WEAVE, Wingspan Stent System Post Market Surveillance.